摘要

Objectives: Define the estrogen-depleted skin (EDS) phenotype of menopause; review therapeutic strategies across lifestyle, cosmeceuticals, biostimulators, and hormones; present a holistic framework to optimize outcomes for midlife women. Introduction: During menopause, estrogen loss accelerates aging with rapid collagen decline, dermal thinning, and tissue deflation. EDS manifests as wrinkles, sensitivity, volume loss, and skeletal remodeling. Recognizing these stigmata allows targeted interventions to protect skin health and aesthetics. Materials / method: A review of published literature (PubMed, MEDLINE, 2000–2024) on menopause, estrogen-depleted skin, and aesthetic therapies was combined with Dr. Pearlman’s clinical experience and case series from her longevity and aesthetic practice. Interventions were assessed across four levels: -Lifestyle & Nutraceuticals -Cosmeceuticals & Topicals -Biostimulatory & Regenerative Therapies -Hormonal & Hormone Analogues Results: Collagen loss and dermal thinning in postmenopausal women are significantly mitigated with estrogen therapy; emerging evidence suggests therapeutic benefits with selective non-estrogenic modulators and bioactive peptides. Combination strategies (PLLA + exosomes + cosmeceuticals) are likely to deliver best outcomes in hydration, tone, and radiance. Early data suggest SERMs and NERAs restore estrogenic benefits without systemic risks. Conclusion: The estrogen-depleted face is predictable but preventable. Aesthetic physicians should integrate lifestyle, regenerative, and evolving hormone-based approaches. Dr. Pearlman’s Menopausal Aesthetics framework provides practical pearls to preserve skin vitality and empower women through the menopause transition and beyond.